Salix Pharmaceuticals Ltd.
http://www.salix.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Salix Pharmaceuticals Ltd.
Zydus’s ‘Transparency Failure’ Leads To Block On Indian Perjeta Biosimilar
“The principles of fairness in procedural conduct, especially in commercial disputes, is crucial,” Delhi’s High Court told Zydus Lifesciences as it agreed to temporarily block the sale of the firm’s recently launched biosimilar to Roche’s Perjeta.
Reddy’s, Zydus Shake Hands On Next-Generation Pertuzumab In India
Two major Indian players have formed an alliance to bring a biosimilar to Genentech’s Perjeta to their local market, having already debuted several treatments in the HER2-positive breast cancer space.
India Pharma Chiefs On Supply Chain Learnings From Auto Sector, New ‘PAGE’ On Skilling
Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.
ANDA Suitability Petitions: The Timelines They Are A-Changin'
US suitability petition submissions see an uptick against the backdrop of GDUFA III new goals for the FDA's response to such petitions. The Pink Sheet tracks some of the activity as applicants seek to tap market opportunities without the need for new clinical data.
Company Information
- Other Names / Subsidiaries
-
- InKine Pharmaceutical
- Oceana Therapeutics, LLC
- Q-Med Scandinavia, Inc.
- Santarus, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice